# Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment

> **NCT05113290** · PHASE4 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 66 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Recombinant Human Adenovirus Type 5 injection
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT05113290
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-28
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113290, "Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05113290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*